{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T06:46:57Z","timestamp":1775890017503,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T00:00:00Z","timestamp":1426550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-015-0855-6","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T14:38:20Z","timestamp":1426516700000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients"],"prefix":"10.1186","volume":"15","author":[{"given":"Eric J","family":"Bow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"Vanness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver A","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David I","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lael","family":"Cragin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa J","family":"Shaul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haran","family":"Schlamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,17]]},"reference":[{"issue":"8","key":"855_CR1","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1086\/651263","volume":"50","author":"DP Kontoyiannis","year":"2010","unstructured":"Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091\u2013100.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"855_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","volume":"102","author":"T Fukuda","year":"2003","unstructured":"Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102(3):827\u201333.","journal-title":"Blood"},{"issue":"3","key":"855_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1086\/595846","volume":"48","author":"D Neofytos","year":"2009","unstructured":"Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265\u201373.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"855_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1086\/522189","volume":"45","author":"L Pagano","year":"2007","unstructured":"Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study\u2013Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007;45(9):1161\u201370.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"855_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):427\u201331.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"855_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/bmt.2010.175","volume":"46","author":"J Maertens","year":"2011","unstructured":"Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20132009 update. Bone Marrow Transplant. 2011;46(5):709\u201318.","journal-title":"Bone Marrow Transplant"},{"issue":"6b","key":"855_CR7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1445-5994.2008.01723.x","volume":"38","author":"MA Slavin","year":"2008","unstructured":"Slavin MA, Heath CH, Thursky KA, Morrissey CO, Szer J, Ling LM, et al. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Intern Med J. 2008;38(6b):468\u201376.","journal-title":"Intern Med J"},{"issue":"34","key":"855_CR8","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","volume":"25","author":"E Robenshtok","year":"2007","unstructured":"Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34):5471\u201389.","journal-title":"J Clin Oncol"},{"issue":"2","key":"855_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.clinthera.2013.11.010","volume":"36","author":"PD Ziakas","year":"2014","unstructured":"Ziakas PD, Kourbeti IS, Mylonakis E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin Ther. 2014;36(2):292\u2013306.","journal-title":"Clin Ther"},{"issue":"3","key":"855_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","volume":"155","author":"DI Marks","year":"2011","unstructured":"Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155(3):318\u201327.","journal-title":"Br J Haematol"},{"issue":"9","key":"855_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2165\/11588370-000000000-00000","volume":"29","author":"P Pechlivanoglou","year":"2011","unstructured":"Pechlivanoglou P, De VR, Daenen SM, Postma MJ. Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence. Pharmacoeconomics. 2011;29(9):737\u201351.","journal-title":"Pharmacoeconomics"},{"key":"855_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1745-6215-10-86","volume":"10","author":"C O'Regan","year":"2009","unstructured":"O'Regan C, Ghement I, Eyawo O, Guyatt GH, Mills EJ. Incorporating multiple interventions in meta-analysis: an evaluation of the mixed treatment comparison with the adjusted indirect comparison. Trials. 2009;10:86.","journal-title":"Trials"},{"issue":"20","key":"855_CR13","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105\u201324.","journal-title":"Stat Med"},{"issue":"1","key":"855_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1185\/03007990802633160","volume":"25","author":"SJ Edwards","year":"2009","unstructured":"Edwards SJ, Clarke MJ, Wordsworth S, Welton NJ. Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison. Curr Med Res Opin. 2009;25(1):251\u201361.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"855_CR15","first-page":"e35","volume":"5","author":"B McIntosh","year":"2011","unstructured":"McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011;5(1):e35\u201348.","journal-title":"Open Med"},{"issue":"3","key":"855_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1185\/03007995.2012.659724","volume":"28","author":"A Migliore","year":"2012","unstructured":"Migliore A, Broccoli S, Massafra U, Bizzi E, Frediani B. Mixed-treatment comparison of anabolic (teriparatide and PTH 1\u201384) therapies in women with severe osteoporosis. Curr Med Res Opin. 2012;28(3):467\u201373.","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"855_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","volume":"104","author":"EJ Mills","year":"2011","unstructured":"Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109\u201324.","journal-title":"QJM"},{"issue":"2","key":"855_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1136\/annrheumdis-2011-200228","volume":"71","author":"S Schmitz","year":"2012","unstructured":"Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71(2):225\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"855_CR19","doi-asserted-by":"publisher","first-page":"i25","DOI":"10.1093\/jac\/dkq439","volume":"66","author":"N Freemantle","year":"2011","unstructured":"Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother. 2011;66 Suppl 1:i25\u201335.","journal-title":"J Antimicrob Chemother"},{"key":"855_CR20","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1476-0711-8-23","volume":"8","author":"EJ Mills","year":"2009","unstructured":"Mills EJ, Perri D, Cooper C, Nachega JB, Wu P, Tleyjeh I, et al. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis. Ann Clin Microbiol Antimicrob. 2009;8:23.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"855_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1086\/323335","volume":"34","author":"S Ascioglu","year":"2002","unstructured":"Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7\u201314.","journal-title":"Clin Infect Dis"},{"key":"855_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS \u2013 a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325\u20137.","journal-title":"Stat Comput"},{"issue":"1","key":"855_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2010.04.025","volume":"76","author":"H Wang","year":"2010","unstructured":"Wang H, Huang T, Jing J, Jin J, Wang P, Yang M, et al. Effectiveness of different central venous catheters for catheter-related infections: a network meta-analysis. J Hosp Infect. 2010;76(1):1\u201311.","journal-title":"J Hosp Infect"},{"issue":"15","key":"855_CR24","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1002\/sim.2112","volume":"24","author":"PC Lambert","year":"2005","unstructured":"Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med. 2005;24(15):2401\u201328.","journal-title":"Stat Med"},{"key":"855_CR25","first-page":"108","volume-title":"Meta-Analysis in Medicine and Health Policy","author":"W DuMouchel","year":"2000","unstructured":"DuMouchel W, Normand S-L. Computer-modeling and graphical strategies for meta-analysis. In: Stangl DK, Berry DA, editors. Meta-Analysis in Medicine and Health Policy. New York, NY: Marcel Dekker, Inc; 2000. p. 108\u201354."},{"issue":"4","key":"855_CR26","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","volume":"103","author":"KA Marr","year":"2004","unstructured":"Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527\u201333.","journal-title":"Blood"},{"issue":"4","key":"855_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"24","key":"855_CR28","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","volume":"116","author":"JR Wingard","year":"2010","unstructured":"Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116(24):5111\u20138.","journal-title":"Blood"},{"issue":"9","key":"855_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","volume":"138","author":"DJ Winston","year":"2003","unstructured":"Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705\u201313.","journal-title":"Ann Intern Med"},{"issue":"3","key":"855_CR30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/TP.0b013e3182577485","volume":"94","author":"AM Chaftari","year":"2012","unstructured":"Chaftari AM, Hachem RY, Ramos E, Kassis C, Campo M, Jiang Y, et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. Transplantation. 2012;94(3):302\u20138.","journal-title":"Transplantation"},{"issue":"10","key":"855_CR31","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.bbmt.2012.03.014","volume":"18","author":"X Huang","year":"2012","unstructured":"Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012;18(10):1509\u201316.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"855_CR32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ajh.10234","volume":"71","author":"LP Koh","year":"2002","unstructured":"Koh LP, Kurup A, Goh YT, Fook-Chong SM, Tan PH. Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol. 2002;71(4):260\u20137.","journal-title":"Am J Hematol"},{"issue":"5","key":"855_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0002-9343(01)01127-5","volume":"112","author":"ML MacMillan","year":"2002","unstructured":"MacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med. 2002;112(5):369\u201379.","journal-title":"Am J Med"},{"issue":"6","key":"855_CR34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","volume":"171","author":"MA Slavin","year":"1995","unstructured":"Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2013a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545\u201352.","journal-title":"J Infect Dis"},{"issue":"8","key":"855_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/sj.bmt.1702233","volume":"25","author":"SN Wolff","year":"2000","unstructured":"Wolff SN, Fay J, Stevens D, Herzig RH, Pohlman B, Bolwell B, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant. 2000;25(8):853\u20139.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"855_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417\u201328.","journal-title":"Value Health"},{"issue":"23","key":"855_CR37","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1002\/cncr.24628","volume":"115","author":"M Adamina","year":"2009","unstructured":"Adamina M, Tomlinson G, Guller U. Bayesian statistics in oncology: a guide for the clinical investigator. Cancer. 2009;115(23):5371\u201381.","journal-title":"Cancer"},{"issue":"38","key":"855_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4380","volume":"4","author":"DJ Spiegelhalter","year":"2000","unstructured":"Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess. 2000;4(38):1\u2013130.","journal-title":"Health Technol Assess"},{"issue":"5","key":"855_CR39","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jclinepi.2009.01.012","volume":"62","author":"D Schwartz","year":"2009","unstructured":"Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009;62(5):499\u2013505.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"855_CR40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jclinepi.2008.12.011","volume":"62","author":"KE Thorpe","year":"2009","unstructured":"Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62(5):464\u201375.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"855_CR41","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","volume":"18","author":"K Claxton","year":"1999","unstructured":"Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ. 1999;18(3):341\u201364.","journal-title":"J Health Econ"},{"key":"855_CR42","first-page":"48104-3209","volume-title":"The Cult of Statistical Significance: How the Standard Error Costs Us Jobs, Justice, and Lives","author":"ST Ziliak","year":"2008","unstructured":"Ziliak ST, McCloskey DN. The Cult of Statistical Significance: How the Standard Error Costs Us Jobs, Justice, and Lives. Ann Arbor, MI: University of Michigan Press; 2008. p. 48104-3209."},{"key":"855_CR43","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1080\/01621459.2000.10474331","volume":"95","author":"BP Carlin","year":"2000","unstructured":"Carlin BP, Louis TA. Empirical Bayes: Past, Present and Future. J Am Stat Assoc. 2000;95:1286\u20139.","journal-title":"J Am Stat Assoc"},{"issue":"4","key":"855_CR44","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1007\/s12032-009-9339-0","volume":"27","author":"J Wang","year":"2010","unstructured":"Wang J, Zhan P, Zhou R, Xu J, Shao X, Yang Y, et al. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials. Med Oncol. 2010;27(4):1082\u20138.","journal-title":"Med Oncol"},{"issue":"12","key":"855_CR45","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/bmt.2010.38","volume":"45","author":"O Blennow","year":"2010","unstructured":"Blennow O, Remberger M, Klingspor L, Omazic B, Fransson K, Ljungman P, et al. Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT. Bone Marrow Transplant. 2010;45(12):1710\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"855_CR46","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B Pauw de","year":"2008","unstructured":"de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"855_CR47","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/cid\/ciu911","volume":"60","author":"R Herbrecht","year":"2015","unstructured":"Herbrecht R, Patterson TF, Slavin MA, Marchetti O, Maertens J, Johnson EM, et al. Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole versus Amphotericin B for Therapy of Invasive Aspergillosis. A Collaborative Study of the Mycoses Study Group (MSG 05) and the EORTC Infectious Diseases Group. Clin Infect Dis. 2015;60(5):713\u201320.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"855_CR48","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1086\/590566","volume":"47","author":"BH Segal","year":"2008","unstructured":"Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47(5):674\u201383.","journal-title":"Clin Infect Dis"},{"key":"855_CR49","volume-title":"US prescribing information (last update June 2012)","author":"Merck Sharp & Dohme Corp Noxafil (posaconazole) oral suspension","year":"2012","unstructured":"Merck Sharp & Dohme Corp Noxafil (posaconazole) oral suspension. US prescribing information (last update June 2012). 2012."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-015-0855-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0855-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0855-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0855-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T01:33:53Z","timestamp":1566437633000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-015-0855-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,17]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1186\/s12879-015-0855-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,17]]},"assertion":[{"value":"3 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"128"}}